CNS trials, including Neurology and Psychiatry, have some of the lowest success rates compared to other therapeutic areas. There are many factors that contribute to this such as: Reliance on subjective endpoints, challenges with consenting, and patient burden due to long trial durations. THREAD understands these challenges and has a proven track record supporting these trials through a holistic approach. We have found that it is necessary to select and develop new endpoints, while listening to patients, taking into account their unique considerations, making research better overall. With over 30 rare disease neurology studies including those with severe neurodegeneration, our teams understand the complex support required to ensure participants and their care teams stay engaged and data is collected reliably on time.